Yup, this is a new one. A good listen, much of it
Post# of 148190
(Total Views: 428)
Posted On: 11/26/2019 9:35:17 PM
Re: ClosetInvestor #11570
Yup, this is a new one. A good listen, much of it is rehash but the newer information I got out of it.
1. Slowing down on monotherapy for a bit after talking with Senators about the Prep possibilities. The senators were excited, so hoping to get breakthrough designation for Prep before moving on to monotherapy.
2. Non-US companies in talks for licensing with mTNBC after results from first patient
3. Apparently our share price has taken a beating (was anyone else aware?)
4. Nash results sent to other pharmaceuticals
The end was just a rehash of the press releases, although he mentioned Dr. Maddon the inventor of the drug is even impressed with how well leronlimab is blocking the CCR5 and is excited about how things are progressing.
A decent listen...and yes NP said matter of fact the HIV license deal is still on and they will be getting to revenue.
Happy Holidays everyone!
1. Slowing down on monotherapy for a bit after talking with Senators about the Prep possibilities. The senators were excited, so hoping to get breakthrough designation for Prep before moving on to monotherapy.
2. Non-US companies in talks for licensing with mTNBC after results from first patient
3. Apparently our share price has taken a beating (was anyone else aware?)
4. Nash results sent to other pharmaceuticals
The end was just a rehash of the press releases, although he mentioned Dr. Maddon the inventor of the drug is even impressed with how well leronlimab is blocking the CCR5 and is excited about how things are progressing.
A decent listen...and yes NP said matter of fact the HIV license deal is still on and they will be getting to revenue.
Happy Holidays everyone!
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼